A prospective, multi centre, randomized clinical study to compare the efficacy and safety of Ertapenem 3 days versus Ampicillin - Sulbactam 3 days in the treatment of localized community acquired intra-abdominal infection. (T.E.A. Study: Three days Ertapenem vs three days Ampicillin-sulbactam) by Coccolini, Federico et al.
STUDY PROTOCOL Open Access
A prospective, multi centre, randomized clinical
study to compare the efficacy and safety of
Ertapenem 3 days versus Ampicillin - Sulbactam
3 days in the treatment of localized community
acquired intra-abdominal infection. (T.E.A. Study:










4 and Antonio D Pinna
1
Abstract
Background: The recommendations outlined in the latest guidelines published by the Surgical Infection Society
(SIS) and the Infectious Disease Society of America (IDSA) regarding the proper duration of antibiotic therapy in
patients with intra-abdominal infections are limited and non-specific. This ambiguity is due mainly to the lack of
clinical trials on the topic of optimal duration of therapy. It is well known that the overuse of antibiotics has several
important consequences such as increased treatment costs, reduced clinical efficacy, and above all, the increased
emergence of antibiotic-resistant pathogens. Ampicillin-Sulbactam is a commonly used “first line” antibiotic for
intra-abdominal infections. Ertapenem and Ampicillin-sulbactam are recommended as primary treatment agents for
localized peritonitis by both the SIS and IDSA guidelines.
Methods/Design: This study is a prospective multi-center randomized investigation. The study will be performed
in the Departments of General, Emergency, and Transplant Surgery of Sant’Orsola-Malpighi University Hospital in
Bologna, Italy, in the General Surgery Department of the Ospedali Riuniti of Bergamo, Italy, and in the Trauma and
Emergency Surgery Department of Maggiore Hospital in Bologna, Italy, and will be conducted by all surgeons
willing to participate in the study. The inclusion period of the study will take approximately two years before the
planned number of 142 enrolled patients is reached.
Discussion: Ertapenem and Ampicillin-sulbactam are recommended both as primary treatment agents for localized
peritonitis by both the SIS and IDSA guidelines. As one of the discussed topic is the optimal duration of the
antibiotic therapy and this ambiguity is due mainly to the lack of clinical trials on the topic, the present study aims
for obtain precise data.
Trial Registration: ClinicalTrials.gov: NCT00630513
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The recommendations outlined in the latest guidelines
published by the Surgical Infection Society (SIS) and the
Infectious Disease Society of America (IDSA) regarding
the proper duration of antibiotic therapy in patients
with intra-abdominal infections are limited and non-spe-
cific According to these guidelines, an “antimicrobial
therapy for established infections should be continued
until resolution of clinical signs of infection occurs,
including normalization of temperature and WBC count
and return of gastrointestinal function” [1].
Such ambiguity is primarily attributable to the lack of
clinical trials conducted on the topic of the optimal
duration of antibiotic therapy.
These vague guidelines have manifested themselves in
clinical practice; in most trials for antibiotic therapy, a fixed
period ranging from 5 to 14 days is used for all patients
presenting with community-acquired intra-abdominal
infection, irrespective of severity of the peritonitis.
It should be noted that secondary peritonitis encom-
passes several different diseases and, as such, its severity
has been known vary significantly [2].
I th a sb e e nd e m o n s t r a t e dt h a tm o s tp a t i e n t se n r o l l e d
in trials involving antibiotic treatment of IAI present
with a mild form of the acute illness, which in 35-55%
(and, in some studies, up to 70%) of cases is represented
by acute appendicitis [3]. It should also be noted that
many patients do not suffer from a fully developed and
widely spread infection but rather experience a localized
infection or simple contamination [4].
This means that many patients receive superfluous
and unnecessary antibiotic treatments. Many non-ran-
dom trials demonstrated that, by tailoring the duration
of the antibiotic therapy to the extent of the infection as
assessed during surgery, the same clinical results could
be obtained in all groups of treated patients without the
use of excessive antibiotic treatment regimens [5]. A
recent systematic meta-analysis of twenty-eight studies
on the duration of antibiotic therapy in cases of
advanced pediatric appendicitis demonstrated that limit-
ing the duration of antibiotic use to only 3 days was not
associated with higher rates of intra-abdominal abscesses
or wound infection [5].
In 2006, Basoli et al. demonstrated in a randomized
study that a shorter duration of Ertapenem is as effec-
tive as a standard 5-day treatment regimen in patients
presenting with mild-moderate peritonitis, thereby
resulting in a significant reduction in the excessive use
of antibiotics. These results represent a much-needed
reassessment of antibiotic treatment and a conservative
shift in antibiotic regimen methodology [6].
It is well known that the overuse of antibiotics has
several important consequences such as increased
treatment costs, reduced clinical efficacy, and above all,
the increased emergence of antibiotic-resistant patho-
gens. The use of excessive or otherwise inappropriate
antibiotic regimens may facilitate the emergence of
resistant bacterial strains [7].
The fact that Ertapenem appears to be an effective
monotherapy for community-acquired IAI is particularly
important.
Ertapenem is a long-term acting parenteral Group I
carbapenem, which is active in vitro against most aero-
bic and anaerobic bacteria generally associated with
community-acquired infections[8,9]. Ertapenem is not
active against most Pseudomonas aeruginosa or entero-
cocci, but prevention of such strains is not routinely
required for successful treatment of intra-abdominal
infections[10,11].
In an earlier double-blind randomized clinical trial,
Ertapenem proved to be just as effective as piperacillin-
tazobactam [12].
Ampicillin-sulbactam (AS) is a widely used “first line”
antibiotic for treating IAI.
Ertapenem and AS are recommended as single agents
for localized peritonitis in both the SIS and IDSA
guidelines.
The AS daily dosage is 3 g × 3 compared to Ertape-
nem, which is a 1 g single administration.
In Italy, 1 g of Ertapenem costs 36 euros while 1 g of
AS costs only 0.23 euros.
Escherichia coli is the most common bacterium
involved in localized community-acquired IAI; unpub-
lished data from a retrospective analysis of 300 cases
from Sant’Orsola-Malpighi’s General Surgery Depart-
ment reported a growing rate of resistance of Escheri-
chia coli to AS as high as 30% [13].
T h ea i mo ft h i ss t u d yi st oc o m p a r et h er e s u l t so f
Ertapenem administered in a short 3-day regimen (in
terms of efficacy and safety) to a short 3-day regimen of
AS for patients presenting with community-acquired IAI
of mild to moderate severity.
Methods
Design
This study is a prospective multi-center randomized
investigation. The study will be performed in the
Departments of General, Emergency, and Transplant
Surgery of Sant’Orsola-Malpighi University Hospital of
Bologna, in the General Surgery Department of the
Ospedali Riuniti of Bergamo, and in the Trauma and
Emergency Surgery Department of Maggiore Hospital of
Bologna, and will be conducted by all surgeons willing
to participate in the study. The study has been designed
and will be conducted in compliance with the regula-
tions outlined in “Good Clinical Practice” methodology.
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lin-Sulbactam (AS 3 g × 3/day administered intrave-
nously) is compared to a 3-day regimen of Ertapenem
(1 g/day administered intravenously) for treating
patients with localized peritonitis in a blinded evaluation
of established efficacy-based endpoints. Evaluation of
success or failure is blinded by the use of designated
third party administrators who are unaware of the treat-
ments assigned to the patients.
Randomization
The randomization will be achieved by means of a com-
puter-generated assignment system (a randomization
algorithm). The results of this randomization will be
sealed in numbered envelopes. Following the diagnosis of
localized peritonitis, if the patient meets the inclusion
criteria and if he/she is willing to participate in the study,
the patient will sign a document verifying informed con-
sent at which time the attending surgeon will disclose the
contents sealed within the assigned envelope to deter-
mine the patient’s randomly assigned treatment group.
The attending surgeon will then record the patient
name and envelope number.
Statistics
Each group will consist of 71 patients (142 patients for the
entire study). All randomized patients (Intention to Treat
Population) will be included in the analysis. Sample size
has been calculated to reach a confidence level of 95%
w i t hap o w e ro f8 0 % .As a m p l es i z eo f7 1p a t i e n t sh a s
been calculated assuming that Ertapenem can decrease the
rate of “failure” from 30% to 10% as compared to AS.
The statistical analysis will be carried out using Epi
Info 2000, Version 1.1 software package (Dean AG,
Arner TG, Sangam S, Sunki GG, Friedman R, Lantinga
M, Zubieta JC, Sullivan KM, Smith DC. Epi Info 2000, a
database and statistics program for public health profes-
sionals for use with Windows 95, 98, NT, and 2000
computers; Centers for Disease Control and Prevention,
Atlanta, Georgia, USA, 2000). The data generated in this
study will be analyzed in two ways. Researchers will use
the continuous numerical data to perform an analysis of
variance (ANOVA), given that this method can discrimi-
nate between two continuous populations. Discrete data
will be analyzed using the Chi-squared test or Fisher
exact test, as appropriate. Differences between the two
study groups will be considered statistically significant
for p-values less than 0.05 (p < 0.05).
Inclusion and Exclusion Criteria
Inclusion criteria
￿ Adult patients (>18 years of age)
￿ Patients requiring surgical intervention within 24
hours of diagnosis.
￿ Localized IAI (i.e., infection extending beyond the
organ wall but confined by the closest hollow
viscera, mild to moderate in severity):
￿ Acute appendicitis: Ruptured or perforated with
abscess(es)
￿ Acute diverticulitis with perforation and/or abscess
(es)
￿ Acute cholecystitis (including gangrenous cases)
with either rupture or perforation
￿ Acute gastric and duodenal perforation (> 24
hours)
￿ Traumatic perforation of the intestines (> 12
hours)
￿ Secondary peritonitis due to perforated viscera
￿ Intra-abdominal abscess(es) (including those affect-
ing both liver and spleen)
Exclusion criteria
￿ Traumatic bowel perforation requiring surgery
within 12 hours
￿ Perforation of gastroduodenal ulcers requiring sur-
gery within 24 hours
￿ Other intra-abdominal diseases in which the pri-
mary etiology was unlikely to be infectious.
￿ Patients lactating or pregnant
￿ Patients with history of allergy, hypersensitivity, or
any severe reaction to the study antibiotics
￿ Patients with rapidly progressive or terminal
illnesses;
￿ Patients with a history or presence of severe hepa-
tic or renal disease (e.g. creatinine clearance < 0.5
ml/min/1.73 m2);
￿ Patients with a concomitant infection that would
interfere with the evaluation of responses to the
study antibiotics.
Surgical Intervention
Upon patient enrollment, the severity of the disease is
evaluated by means of an APACHE II score and MPI
prior to the operation. Diagnosis is based on the
patient’s clinical symptoms and intra-operative findings,
including intra-operative cultures. The drug regimen
being studied begins prior to surgery. The patients
undergo surgery and then receive a 3-day treatment of
either Ertapenem (1 g per day) or AS (3 g, 3× per day),
depending on the assigned treatment group. Administra-
tion of the antibiotic therapy is then discontinued for
those patients demonstrating an improved temperature
(< 37.8°C), decreased WBC (returning to the normal
range), and the presence of abdominal sounds by the
third day of treatment.
In order to balance the treatment groups, the patients
are stratified according to the site of infection; cases are
either categorized under “complicated appendicitis” or
they are filed under the all-encompassing group, “all
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complicated appendicitis, we have limited the enrollment
into a stratum when almost 50% of cases are enrolled.
Considering that an adequate surgical source control is a
crucial factor determining the outcome of this disease, a
blinded panel of three surgeons is asked to impartially
assess the efficacy of the surgical procedure.
Aerobic and anaerobic cultures of intra-operatively
retrieved specimens are obtained at baseline and pro-
cessed in the clinical microbiology laboratories of the
participating hospitals. All microorganisms are isolated,
cultured, and tested for in vitro susceptibility to the
study antibiotic by disk diffusion or microtiter dilution.
Routine susceptibility testing of strict anaerobes is not
required by treatment protocols.
Data Collection
Patient data sheets are generated containing demo-
graphic figures as well as preoperative, operative, and
postoperative information.
Upon enrollment, all patients undergo physical exami-
nations and laboratory tests, (including a CBC with a
WBC, differential analysis, platelet count, serum glucose
assessment, BUN, and serum creatinine test). The same
procedure is performed on the third day of the treatment
regimen, at the end of the treatment cycle following the
resolution of pathology, and during the post-treatment
follow-up analysis (or more frequently as clinically rele-
vant). Liver function studies, serum electrolytes, and uri-
nalysis are performed upon the discontinuation of the
intravenously administered antibiotic as well as periodi-
cally throughout the treatment process as clinically indi-
cated. When clinically indicated during the course of
antibiotic therapy, blood, urine and tissue specimens
from clinically relevant intra-abdominal sites are
obtained for culture and susceptibility testing. Such cul-
tures are also performed at the end of antibiotic therapy,
unless there is no material available for cultures and/or
no clinical evidence of infection.
The clinical outcomes of eligible patients are classified
in three groups: successful (no signs or symptoms of
infection and no further need for antimicrobial therapy);
failure (indicating no improvement, infection progres-
sion, or death due to infection); or late failure (indicat-
ing recurrence between cessation of antibiotic therapy
and follow-up). Microbiological reports are recorded for
each baseline pathogen. Favorable microbiological
responses involve eradication of the pathogen(s),
assessed on either a documented or presumptive basis
(the latter occurring when there is no material available
for culture in clinically recovered patients). By contrast,
unfavorable microbiologic responses involve a chronic
persistence of the pathogen(s), either on a documented
or presumptive basis.
Any and all adverse events (AEs) that occur during
the course of the study, beginning from the time of ran-
domization, are carefully documented. These AEs are
identified and described by the primary investigators.
Informed Consent or Information Sheet
In the informed consent document, the patient will
review all relevant information about the study protocol
and the confidentiality of personal data. After signing
the informed consent form, the patient will fill out a
questionnaire. The patients will experience minimal
bureaucratic inconveniences during the enrollment pro-
cedure. No incentives are planned for the patients
regarding the surgical operation or the follow-up analy-
sis. All of the patients’ medical information will remain
confidential and will only be accessed by the research
scientists conducting the study. The patients are per-
mitted to withdraw from the study at any time without
any further commitments or obligations.
Ethical Approval
The study has been approved by the Ethics Committee
of St. Orsola-Malpighi Hospital
Primary Endpoint
The study’s primary endpoint is to compare the failure
rates of shortened Ertapenem and AS antibiotic thera-
pies in treating localized IAI.
Secondary Endpoints
The study’s secondary endpoints include the observation
and recording of onsets of any other complications as
assessed intra-operatively, postoperatively, at the time of
discharge, and during 7-day, 1-month, and 6-month fol-
low-up analyses.
The late failure rates and total costs of the antibiotic
therapy regimens will also be recorded.
No incentives are planned for the patients regarding
the surgical operation or the follow-up analysis.
It has been estimated that the study’si n c l u s i o np e r -
iod will take approximately two years. According to
the number of localized IAI cases reported on
a monthly basis by the surgeons of Sant’Orsola-
Malpighi’s General Surgery Department, the inclusion
period of the study will require approximately two
years before the planned number of 142 enrolled
patients is reached.
Interim reports will be conducted after each follow-up
period.
List of abbreviations
WBC: White Blood cell Count; IAI: Intra-Abdominal Infection; AS: Ampicilli-
Sulbactam; SIS: Surgical Infection Society; IDSA: Infectious Diseases Society of
America; BUN: Blood Urea Nitrogen; CBC: Complete Blood Count; MPI:
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